Zai Lab has a broad and validated late-stage pipeline in oncology and infectious disease. We currently have 2 products commercialized and 3 drugs approved in the U.S. (marked with * below). Overall, our pipeline consists of over 15 drug candidates with over 20 ongoing or planned clinical trials.

Oncology
Molecule Name
Potential Indication
Phase
Pre-clinical
Phase 1
Phase 2
Phase 3
NDA Filed
Marketed
Niraparib
Ovarian Cancer (2nd line maintenance) */PK Study
Mainland China, HK & Macau (China)
Ovarian Cancer (1st line maintenance)
IO Combo in Gastric, Ovarian, Non Small Cell Lung Cancer (NSCLC)
Tumor Treating Fields
Glioblastoma (GBM) *- Optune
Hong Kong (China)
Mesothelioma*
NSCLC
Brain Metastases
Pancreatic Cancer
Ovarian Cancer
Gastric Cancer
Ripretinib
Gastrointestinal Stromal Tumors (GIST) (4th Line)
GIST (2nd Line)
Other, i.e. Advanced Systemic Mastocytosis ,Glioma
Margetuximab
HER2+ Breast Cancer
HER2+ Gastric Cancer [2]
INCMGA0012 (PD-1)
Merkel cell, Anal, MSI-high Endometrial
NSCLC and other solid tumors
MGD-013
Gastric[1]
Other, i.e. Triple-negative Breast Cancer (TNBC), NSCLC, HCC, etc.[2]
Bemarituzumab
Gastric Cancer, Gastroesophageal Junction (GEJ)
Brivanib
Hepatocellular Carcinoma (HCC) [2]
Omadacycline
No data!
Durlobactam
No data!
Infectious Disease and Autoimmune
Molecule Name
Potential Indication
Phase
Pre-clinical
Phase 1
Phase 2
Phase 3
NDA Filed
Marketed
Niraparib
No data!
Tumor Treating Fields
No data!
Ripretinib
No data!
Margetuximab
No data!
INCMGA0012 (PD-1)
No data!
MGD-013
No data!
Bemarituzumab
No data!
Brivanib
No data!
Omadacycline
Acute Bacterial Skin and Skin Structure Infection (ABSSSI) *
Community-Acquired Bacterial Pneumonia (CABP) *
Durlobactam
A.Baumanii Bacterial Infections

Note: [1] Combo and mono therapy  [2] Combo therapy